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The quality control of glycoprotein 
folding. An overview 
 
The N-glycan-dependent quality 
control mechanism of glycoprotein 
folding was initially proposed by Ari 
Helenius and co-workers several years 
ago. With a few minor modifications it is 
still valid today (Fig. 1) (1-3). Glycan 
processing starts immediately after its 
transfer from a dolichol-P-P derivative 
to Asn residues in nascent polypeptide 
chains entering the lumen of the 
endoplasmic reticulum (ER). Removal 
of the outermost and following glucoses 
by the successive action of 
glucosidases I and II (GI and GII) 
exposes the Glc1Man9GlcNAc2 epitope 
(Fig. 2). This structure is then 
recognized by two ER resident lectins 
(calnexin, CNX and calreticulin, CRT) 
that specifically bind monoglucosylated 
polymannose glycans. This is followed 
by removal of the innermost  glucose by 
GII, thus liberating the glycoprotein 
from the lectin anchor. The protein-
linked glycan is then reglucosylated by 
the soluble ER enzyme UDP-
Glc:glycoprotein glucosyltransferase 
(GT) only if the protein moiety displays 
non native 3-D structures, as this 
enzyme behaves as a conformational 
sensor. Cycles of glycoprotein-
CNX/CRT binding and liberation, 
catalyzed by the opposing activities of 
GT and GII, are terminated once 
glycoproteins attain their native 
structures. Glucose-free glycoproteins 
continue then their transit through the 
secretory pathway. Alternatively, 
permanently misfolded glycoproteins 
may be then transported to the cytosol 
for proteasomal degradation. Lectin-
glycoprotein association not only 
thwarts Golgi exit of folding 
intermediates and irreparably misfolded 
glycoproteins but also enhances folding 
efficiency by preventing aggregation 
and promoting proper disulfide bonding. 
The latter is catalyzed by an 
oxidoreductase of the PDI family 
(ERp57) that exclusively acts on 
glycoproteins as it is loosely associated 
to CNX/CRT. 
 GT is the only component of the 
quality control mechanism that senses 
protein conformations as it recognizes 
hydrophobic amino acid patches 
exposed in molten globule-like 
conformers (4, 5). GT may also 
glucosylate glycoproteins in not fully 
assembled oligomeric complexes 
because it also recognizes hydrophobic 
surfaces exposed as a consequence of 
the absence of subunit components (6).  
 The aim of this review is to give 
an overview of recent reports dealing 
with entrance and exit of glycoproteins 
from CNX/CRT cycles. 
 
Getting in. GII is not what it was 
thought to be 
 
The first step in the pathway 
leading to the entrance of glycoproteins 
into CNX/CRT cycles is the removal of 
the outermost glucose unit from the 
glycan by the membrane enzyme GI. 
This reaction occurs almost 
simultaneously with glycan transfer. 
The rapid GI-mediated deglucosylation 
of the protein-linked glycan, as well as 
the apparent inability of the enzyme to 
remove in vivo (but not in vitro) the 
glucose from the dolichol-P-P-linked 
glycan strongly suggests the existence 
of a supercomplex formed by the 
oligosaccharyltransferase, GI and the 
dolichol derivative, with a very precise 
orientation of the components. 
 http://www.jbc.org/cgi/doi/10.1074/jbc.R700048200The latest version is at 
JBC Papers in Press. Published on February 26, 2008 as Manuscript R700048200
 by guest on N
ovem
ber 21, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 2 
 It was assumed that the sole 
role of GII was that of removing glucose 
residues l and n (Fig. 2). Recent work, 
however, has suggested a regulatory 
role for this enzyme. GII is a soluble 
dimeric protein, from yeast to 
mammals. The  α subunit displays the 
catalytic activity and no ER 
retaining/retrieval sequence, and the β 
subunit bears a KDEL-like sequence at 
its C-terminus, from yeasts 
(Schizosaccharomyces pombe but not 
Saccharomyces cerevisiae) to 
mammals (7-9). This subunit has also a 
sequence stretch with high homology to 
the mannose binding domain of the 
mannose 6-P receptor (10). Disruption 
of the β subunit-encoding gene in the 
fission yeast results in an almost 
complete loss of activity, probably as a 
consequence of a mislocalization of the 
α subunit. It has been shown for the rat 
liver enzyme that the β subunit is not 
required for activity (8, 11). 
Remarkably, disruption of the β subunit 
gene in S. cerevisiae did not affect the 
enzymatic activity or the ER localization 
of the catalytic component but resulted 
in the exclusive in vivo production of 
monoglucosylated protein-linked N-
glycans (9). Thus, the β subunit 
appears to be required for the complete 
removal of glucoses in the budding 
yeast enzyme. In the case of the 
mammalian enzyme apparently two N-
glycans in the same glycoprotein are 
required for the formation of 
monoglucosylated N-glycans in vivo but 
not for the deglucosylation of these last 
compounds (12). For both the S. 
cerevisiae and mammalian GIIs it was 
hypothesized that an interaction of the 
mannose 6-P receptor-like domain of 
the β subunit with N-glycans was 
responsible for results mentioned 
above (9, 12). Furthermore, in the case 
of the mammalian enzyme it was 
proposed that, as both bonds to be 
successively cleaved (Glcα1,3Glc, 
Glcα1,3Man, Fig. 2) are differently 
oriented in space, a transient 
separation between GII single catalytic 
site and the N-glycan occurs after the 
first cleavage. This separation probably 
allows recognition of the 
monoglucosylated epitope by CNX/CRT 
(12). There is an apparent contradiction 
between results obtained with S. 
cerevisiae and mammalian cells as in 
the former case the β subunit is 
apparently required for the second 
cleavage but not for the first one, 
whereas according to the mechanism 
proposed for mammalian GII, the same 
subunit would intervene only in the first 
cleavage. Furthermore, glycoproteins 
bearing only one diglucosylated glycan 
were efficiently completely 
deglucosylated by purified mammalian 
GII (13). The putative regulation of the 
entrance of glycoproteins into 
CNX/CRT cycles by GII certainly merits 
further studies. 
 
What happens once glycoproteins 
are in CNX/CRT cycles?  
 
Although most glycoproteins 
studied so far interact with the lectins, 
apparently not all of them are 
reglucosylated by GT as some of them 
may complete their folding processes 
taking advantage of the initial binding 
triggered by the partial deglucosylation 
of the transferred glycan. GT is not 
required for the viability of single yeast 
or mammalian cells grown under 
normal conditions and even for that of 
certain multicellular organisms as 
plants but disruption of its encoding 
gene was found to be embryonically 
lethal for mice (14-16). These results, 
together with the strict requirement of 
the enzyme for the viability of S. pombe 
only when grown under severe ER 
stress conditions indicates that a 
restricted set of glycoproteins 
absolutely require GT for attaining their 
proper folding with acceptable 
efficiency (17).  There are alternative 
quality control and folding efficiency 
enhancement mechanisms in the ER 
lumen besides the N-glycan dependent 
one. Deficiencies in the latter trigger the 
upregulation of the former ones. 
According to their rates of 
release from CNX/CRT association, 
glycoproteins expressed in fibroblasts 
derived from GT minus mouse embryos 
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could be classified in three classes: in 
the first one the observed rates were 
similar to those of wild type cells (18). 
Glycoproteins in this class represent 
those with only one cycle of association 
with the lectins triggered by partial 
deglucosylation of the transferred 
glycan. In the second class 
glycoproteins heavily dependent on GT-
mediated association with CNX/CRT for 
folding showed an accelerated release 
from the lectins. GT absence resulted, 
as expected, in a lower folding 
efficiency. The most intriguing case was 
that of glycoproteins in the third class 
as they showed a prolonged 
association with CNX/CRT. It was 
speculated that the observed results 
could be due to a protein-protein 
association between the lectins and 
glycoproteins, or alternatively to the fact 
that a seleno-cysteine-containing 
oxidoreductase (Sep15) that forms a 
1:1 complex with GT could play a role 
in assessing and refining the disulfide 
hbond content of glycoproteins in this 
class (18, 19). 
Although Glc1Man9GlcNAc2 
displays the same affinity for CNX and 
CRT, it has been known for several 
years that the set of glycoproteins 
interacting with one or other of the 
lectins only partially overlap. The 
difference observed was at least 
partially related both to the membrane-
bound or soluble status of CNX or CRT, 
respectively, and to the vicinity of the N-
glycans to the membranes (20). The 
use of CNX or CRT deficient cells 
revealed some unexpected results (21): 
expression of viral and cellular 
glycoproteins in CRT null mouse 
embryo fibroblasts and in CNX deficient 
human T lymphoblastoid cells showed 
that loss of either CNX- or CRT-
glycoprotein interaction or both (by 
addition of glucosidase inhibitors to wild 
type cells) affected the process and 
outcome of glycoprotein production as 
well as the fidelity of quality control in a 
variety of ways. Effects were seen in 
the folding rate (which was accelerated 
particularly when CRT was absent), in 
the folding efficiency (which was 
generally reduced), and in the retention 
of incompletely folded glycoproteins in 
the ER (which was affected only when 
association with both lectins was 
abolished). CNX seemed to be more 
important than CRT as folding 
assistant. Loss of CRT had, in fact, only 
marginal consequences, while loss of 
CNX resulted in a dramatic impairment 
of influenza virus HA folding and in a 
more substantial elevation of other 
alternative ER resident chaperones, a 
symptom of ongoing ER stress. 
Totally unexpected results were 
obtained on studying the interaction of 
CNX/CRT and other chaperones with 
cellular and viral glycoproteins 
expressed in cells lacking a functional 
CNX (22). Three variants of the same 
cellular glycoprotein differing in their 
folding competence, the number of 
glycans and their solubility status, that 
in wild type cells were CNX substrates, 
failed to interact with CRT when 
expressed in CNX null fibroblasts. 
Instead, they more strongly interacted 
with BiP. On the contrary, four viral 
glycoproteins (Semliki forest virus E1 
and p62, vesicular stomatitis virus G 
and influenza virus HA) gave different 
results. The first two glycoproteins 
normally interact with both CNX and 
CRT, but in CNX minus cells they 
interacted more abundantly with CRT 
and their maturation proceeded 
normally. In the case of HA, a 
glycoprotein deeply dependent on CNX 
for successful maturation that normally 
interacts with both CNX and CRT, 
absence of the former lectin resulted in 
a persistent interaction with CRT. The 
most surprising result was obtained 
with G protein that normally interacts 
only with CNX. Infection of CNX 
deficient fibroblasts with VSV (viral 
infection was also used to express E1, 
p62 and HA) resulted in the interaction 
of G protein with CRT. As transfection 
of G protein failed to trigger its 
interaction with CRT, it was suggested 
that viral infection somehow subverted 
the normal glycoprotein recognition by 
the ER lectins. This result may explain 
why total inactivation of CNX/CRT 
cycles affects viral replication and 
infectivity but not viability of mammalian 
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cells. Additional expression of individual 
glycoproteins, both of cellular and viral 
origin and in this last case as a result of 
both viral infection and transfection 
must be studied to substantiate this 
very interesting finding.  
 
Getting out. ERAD components that 
recognize glycoproteins 
 
Exit of properly folded 
glycoproteins from CNX/CRT cycles 
poses no conceptual problems as their 
conformations do not allow GT-
mediated reglucosylation. But, how do 
cells recognize that glycoproteins are 
irreparably misfolded or that multimeric 
complexes are definitively unable to 
complete their oligomeric structures, 
and pull them out from futile CNX/CRT 
cycles to allow proteasomal 
degradation to proceed? Although 
intensive work has been dedicated to 
this issue in recent years and 
substantial progress has been made, 
the picture that now emerges is rather 
complex and no clear answer to the 
question is yet available.  
The observation that addition to 
mammalian cells of mannose analogs 
(behaving as ER mannosidase I and/or 
as polymannose lectin inhibitors) 
delayed degradation of misfolded 
glycoproteins prompted the suggestion 
that a “mannose removal time clock” 
regulated disposal. As mannose 
removal is slower than that of glucose 
by GI and GII it was proposed that 
demannosylation of glycoproteins 
staying in the ER for relatively long 
periods as irreparably misfolded 
glycoproteins do was a tag identifying 
molecules to be driven to degradation.  
There are at least two proteins 
in ERAD (ER associated degradation) 
that may interact with polymannose 
chains for pulling misfolded 
glycoproteins out from CNX/CRT 
cycles: ER α-mannosidase I and 
EDEM. Both mammalian and yeast 
cells ER mannosidase I are membrane 
proteins that convert Man9GlcNAc2 to 
Man8GlcNAc2 isomer B (M8B, Fig. 2) 
but they are not as specific as initially 
thought because the recombinant 
species were able to further degrade 
M8B to smaller glycans. However, high 
enzyme concentrations not thought to 
occur in vivo were employed in the 
assays (23). Nevertheless, glycans 
smaller than M8B have been detected 
in glycoproteins forced to stay in the ER 
for rather long time periods as happens 
with irreparably misfolded and ER 
resident glycoproteins (24-26). The 
enzymatic activities responsible for 
further degradation of Man8GlcNAc2 
glycans in the ER have not been 
unequivocally identified yet and they 
might not even be ER resident proteins. 
It is known that irreparably misfolded 
glycoproteins may cycle between the 
ER and Golgi before being driven to 
degradation both in yeast and 
mammalian cells (27-32). Unlike the S. 
cerevisiae Golgi, that is devoid of 
mannosidase activities, mammalian cell 
cis Golgi cisternae display three α-
mannosidase activities able to degrade 
Man9GlcNAc2 to Man5GlcNAc2 
(residues a-e, h and j, Fig. 2) (33, 34).  
Furthermore, mammalian cells, but not 
yeast ones, have an ERGIC-cis Golgi 
endomannosidase that yields M8A (Fig. 
2) and GlcMan as degradation products 
of Glc1Man9GlcNAc2.  
  Genome analysis revealed that 
there are three ER α-mannosidase I 
homologues in mice and only one in 
either S. pombe or S. cerevisiae (35-
40). They were called EDEM (for 
endoplasmic reticulum degradation 
enhancing α-mannosidase-like 
proteins) in mammalian cells and 
Htm1p or Man1p in yeasts. EDEMs 
were first thought to be membrane 
bound but recent work showed them to 
be soluble proteins (41, 42). EDEMs 
display a 450-residue domain that 
shares 35 % sequence identity with the 
catalytic domain of ER α-mannosidase 
I. It was first proposed that EDEMs 
behaved as lectins and not as enzymes 
as they lack a particular disulfide bond 
thought to be required for hydrolytic 
activity, but further sequencing work 
detected several  active fungal 
mannosidases lacking that particular 
bond. It has been reported that 
overexpression of EDEMs enhances 
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misfolded protein degradation by pulling 
those species out from CNX/CRT 
cycles whereas a decrease in EDEM 
amounts, derived from the use of RNAi, 
resulted in a degradation delay (35, 40). 
 
Mechanisms proposed for misfolded 
glycoprotein escape from CNX/CRT 
cycles 
 
Based on a report indicating that 
absence of mannose residues i or i and 
k (Fig. 2) (that is, leaving intact the 3´ 
branch to which Glc is added by GT) 
decreased GT-mediated glucosylation 
rate (43), a first proposal assumed that 
impeded reglucosylation of 
Man8GlcNAc2 or Man7GlcNAc2 glycans 
following GII glucose removal would 
liberate misfolded glycoproteins from 
CNX/CRT cycles (44). However, as an 
earlier report had shown that GII 
displayed a similar rate trend as GT 
concerning N-glycan composition (45), 
according to this proposal misfolded 
glycoprotein degradation would have to 
be the outcome of a delicate balance 
between specificities for glycans and 
relative amounts of GII and GT. A more 
recent communication, however, 
reported similar GII-mediated 
deglucosylation rates for 
G1Man9GlcNAc2 and the 
monoglucosylated derivative of M8B 
(13). Further studies on the GII 
specificity for glycans are required for 
elucidating this discrepancy. 
Nevertheless, it was shown that even 
glycoproteins bearing the Man5GlcNAc2 
structure (residues a-g, Fig. 2) were 
good GT substrates in vivo and the 
resulting glucosylated glycoproteins 
interacted with CNX (46).  
A second proposal was based 
on the observation that EDEMs 
interacted with totally deglucosylated 
misfolded glycoproteins, whereas CNX 
associated with monoglucosylated 
species, and suggested that EDEMs, 
behaving as lectins, physically 
interacted with the glycans, thus 
hindering GT mediated reglucosylation 
(41, 47). This proposal implies that 
EDEMs should be lectins with an 
extremely broad specificity spectrum as 
even glycoproteins synthesized in cells 
transferring Glc3Man5GlcNAc2 (residues 
a-g and l-n, Fig. 2) participate in 
CNX/CRT cycles (46). 
 Finally, a third proposal based 
on the observation that ER α-
mannosidase I overexpression 
accelerated misfolded glycoprotein 
degradation (48), assumed that 
extensive demannosylation, and 
specifically removal of residue g (Fig. 
2), that is, the residue to which GT adds 
the glucose unit, would prevent GT-
mediated reglucosylation and thus 
CNX/CRT glycoprotein interaction. The 
enzymatic activity(ies) responsible for 
such demannosylation has not been 
unequivocally identified yet but several 
possibilities have been advanced: a) 
ER mannosidase I concentrated in 
specific subcellular sites together with 
misfolded glycoproteins (25). Such 
concentration was recently observed for 
a HA-tagged version of ER α-
mannosidase I expressed in 
mammalian cells (49). Confirmation of 
such concentration for the native 
enzyme is necessarily required; b) it 
was recently proposed that EDEMs 
might display enzymatic activity as 
overexpression of EDEM1 and EDEM3 
(EDEM2 has not been tested yet) (35, 
50) results in a more extensive 
demannosylation of misfolded 
glycoproteins. Moreover, EDEM 
mutants defective in amino acids known 
to be essential for ER α-mannosidase I 
activity failed to increase 
demannosylation. The main objection to 
this proposal is that EDEMs have not 
been purified to homogeneity yet, thus 
precluding assaying the enzymatic 
activity of the native species and, 
additionally, no mannosidase activity 
could be detected in recombinant 
EDEMs 1, 2 or 3, although the 
expression of the homologous lumenal 
portion of ER α-mannosidase I gave 
positive results. Furthermore, the 
inability of mutant EDEMs to promote 
extensive N-glycan demannosylation 
might not be a conclusive evidence for 
the enzymatic activity of the α-
mannosidase homologues as for 
instance, mutations might abolish a 
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putative lectin activity responsible for 
hindering GT-mediated reglucosylation 
and c) cis Golgi mannosidases, that as 
mentioned above are able to convert 
Man9GlcNAc2 to Man5GlcNAc2 (Fig. 2), 
and/or ERGIC-cis Golgi 
endomannosidase that yields M8A, an 
isomer lacking residue g (Fig. 2) (33, 
34). A recent paper showed that not 
only overexpression of ER α-
mannosidase I and EDEMs but also 
that of Golgi α-mannosidases IA, IB or 
IC resulted in an enhancement of 
misfolded glycoprotein 
demannosylation and degradation (32). 
It was not shown, however, if the 
overexpressed proteins localized 
exclusively to the Golgi or if they were 
present in the ER as well. 
The second proposal for a 
misfolded glycoprotein escape 
mechanism from CNX/CRT cycles (see 
above) is probably the only one 
applicable to S. pombe, a displaying a 
quality control mechanism similar to 
that occurring in mammalian cells and 
in which disruption of the EDEM-
encoding gene drastically decreased 
the degradation rate of misfolded 
glycoproteins (51). No Man9GlcNAc2 
demannosylation was observed in 
mutants lacking a functional ER α-
mannosidase I encoding gene, thus 
suggesting that the yeast single EDEM 
homologue has no α-mannosidase 
activity. Also, there are no ERGIC-cis 
Golgi endomannosidase or cis Golgi α-
mannosidase activities in S. pombe. 
Finally, even after an extremely long 
residence in the ER, Man9GlcNAc2 in 
misfolded glycoproteins was minimally 
degraded, Man7GlcNAc2 being the 
smallest glycan detected. This last 
compound still had mannose residue g 
(Fig. 2) (51). 
The absence of 
monoglucosylated glycans is not an 
absolute condition for glycoprotein 
degradation: Glc1Man5GlcNAc 
(residues b-g and  l, Fig. 2) was found 
to be a cytosolic byproduct of the 
degradation of misfolded glycoproteins 
synthesized by Chinese hamster ovary 
mutant cells known to transfer 
Man9GlcNAc2 in protein N-glycosylation 
(52). The glycan came from cytosolic 
degradation of Glc1Man9GlcNAc2 and 
Glc1Man8GlcNAc2, the species that 
determined CNX/CRT recognition of 
folding intermediates in those cells. 
These results show that diversion to 
degradation of misfolded glycoproteins 
cannot be solely ascribed to their 
liberation from CNX/CRT anchors 
caused by hindering formation of 
monoglucosylated N-glycans.  
 
 
Do CNX/CRT behave also as 
classical chaperones? 
 
Although binding of most known 
substrates to CRT and CNX appears to 
be mediated exclusively by the glycan 
moiety, in some cases the lectins may 
apparently display a behavior more 
akin to that observed in classic 
chaperones (53). For instance, under 
mild cell lysis conditions some proteins 
remain associated with CNX/CRT even 
in the presence of glucosidase 
inhibitors (54-56). In addition, thermally 
induced aggregation of non-
glycosylated proteins may be 
suppressed in vitro by both CNX and 
CRT (57, 58). In addition, CNX mutants 
devoid of lectin activity may associate 
in vivo with class I histocompatibility 
molecules (59). Interestingly, CRT 
displays a marked preference for 
hydrophobic peptides in in vitro binding 
assays (60). The absence of any 
obvious binding site for hydrophobic 
domains in the structure of CNX 
constitutes a major drawback for the 
occurrence of polypeptide-based 
interactions. Nevertheless, the static 
picture captured in the crystal may 
hinder alternative conformations 
unfavorable under the crystallization 
conditions but able to bind proteins 
displaying non native conformations. 
For instance, upon heat shock or 
calcium depletion both CRT and CNX 
undergo conformational changes that 
induce their oligomerization and 
increase their ability to bind non-
glycosylated substrates (61, 62). ATP 
provides the energy required for 
binding and unbinding cycles of 
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 7 
classical chaperones and the role of 
the nucleotide is played by UDP-Glc in 
CNX/CRT lectin based cycles 
described in this review. Whether 
similar binding-unbinding cycles (and 
their energy purveyor) occur in the 
putative role of CNX/CRT as classical 
chaperones is presently unknow
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Legends to Figures 
 
Fig. 1. Model proposed for the quality control of glycoprotein folding. Proteins 
entering the ER are N-glycosylated by the oligosaccharyltransferase (OST) as they 
emerge from the translocon. Two glucoses are removed by the sequential action of GI 
and GII to generate monoglucosylated species that are recognized by CNX and/or 
CRT (only CNX is shown), that are associated with ERp57. The complex between the 
lectins and folding intermediates/misfolded glycoproteins dissociates upon removal of 
the last glucose by GII, and is reformed by GT activity. Once glycoproteins have 
acquired their native conformations, either free or complexed with the lectins, GII 
hydrolyzes the remaining glucose residue and releases the glycoproteins from the 
lectin anchors. These species are not recognized by GT and are transported to the 
Golgi. Glycoproteins remaining in misfolded conformations are retrotranslocated to the 
cytosol where they are deglycosylated and degraded by the proteasome. One or more 
mannose residues may be removed during the whole folding process. 
 
 
Fig. 2. Structure of glycans. Lettering (a-n) follows the order of addition of 
monosaccharides in the synthesis of Glc3Man9GlcNAc2-P-P-dolichol.  GI removes 
residue n and GII residues l and m. GT adds residue l to residue g. M8A lacks 
residues g and l-n, M8B formed by mammalian cell or yeast ER α-mannosidase I 
lacks residues i, and l-n and M8C residues k and l-n. The smallest glycan formed in S. 
pombe ER (Man7GlcNAc2) lacks residues i, k and l-n. 
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FIGURE 1 
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